Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Neonc Technologies, Inc.
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · IDH-Wildtype Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| neo212 (this asset) | Neonc Technologies, Inc. | P1/2 | CC · 45 |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | National Cancer Institute (NCI) | P2 | B |
| Ipilimumab | Neonc Technologies, Inc. | P2 | B |
| Pembrolizumab | Mayo Clinic | P2 | B |
| Nivolumab | Neonc Technologies, Inc. | P2 | B |
| Cerebraca Wafer | Everfront Biotech Co., Ltd. | P2/3 | B |
| Lomustine | Vastra Gotaland Region | P3 | B |
| Atezolizumab | National Cancer Institute (NCI) | P2 | CCC |
| Adriamycin | Northwestern University | P2 | CCC |
+36 more in the IDH-Wildtype Glioblastoma cohort
Other indications for neo212
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Malignant Neoplasm In The Brain | — | P1/2 | CCC · 48 |
| Astrocytoma, IDH-Mutant, Grade 2 | — | P1/2 | CC · 45 |
| Cutaneous Neuroendocrine Carcinoma | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerNational Cancer Institute (NCI)B
- IpilimumabNeonc Technologies, Inc.B
- PembrolizumabMayo ClinicB
- NivolumabNeonc Technologies, Inc.B
- Cerebraca WaferEverfront Biotech Co., Ltd.B
Citation
Floatz Terminal. neo212 in IDH-Wildtype Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/neo212-idh-wildtype-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →